Cipla Ltd Share Price

Q: What is the share price of Cipla Ltd today?

Cipla Ltd share price as on 22 Jan 2025 is ₹1433.4

Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg

NSE: CIPLA Large Cap ISIN: INE059A01026

As on 22 January 2025 at 12:54 IST

₹1,433.40

+ 5.40

(0.38%)

Sell Buy

About Cipla Ltd

Cipla Ltd is an Indian multinational pharmaceutical company. Founded in 1935 by Khwaja Abdul Hamied as the Chemical, Industrial & Pharmaceutical Laboratories. The company’s headquarters are located in Mumbai, Maharashtra, India. It focuses on developing medications to treat diseases and various other medical conditions. Cipla Ltd operates in the pharmaceutical sector, providing a wide range of drugs, vaccines, and diagnostics. They even make contact lenses, animal health products and dietary supplements. The company is known for its innovation in developing affordable medications, which make it a significant player in the pharmaceutical industry. Read More...

Over 1 Month

-3.26%

Over 6 Months

-4.16%

Over 1 Year

1.35%

Over 3 Years

64.62%

Cipla Ltd Summary

Close ₹ 1,433.40

Open ₹ 1,431.10

High ₹ 1,440.85

Low ₹ 1,420.20

Volume 4,37,953

Net Turnover (in ₹) ₹ 1,18,39,35,319.20

52Wk High ₹ 1,702.05

52Wk Low ₹ 1,312

52Wk High / Low

1,312

1,702.05

Cipla Ltd Fundamentals

Key Financial Data

Market Cap (in ₹Cr) ₹ 1,15,327.28

EPS (TTM) 52.42

Book Value (BV) 360.74

Div. Yield 0.91 %

P/E (TTM) 26.28

Price/Book Value 3.96

Delivery % 38.70 %

Face Value 2

Key Ratios

PE Ratio 29.60

PB Ratio 4.31

EV to Sales 7.26

PEG Ratio 0.48

ROA 14.47

ROE 15.50

Debt-Equity -

Net Profit Margin 24.60

Operating Profit Margin 35.71

Cipla Ltd Financials

Profit and Loss

Consolidated

Standalone

Yearly

Quarterly

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	26,520.66	23,228.57	22,044.25	19,425.58	17,476.19
Total Expenses	20,623.94	19,007.80	18,368.86	16,135.52	15,298.01
Profit Before Tax	5,701.90	4,038.35	3,493.27	3,290.06	2,178.18
Profit After Tax	4,155.31	2,835.49	2,559.47	2,401.30	1,546.98
Operating Profit after Depreciation	5,986.60	4,330.31	3,781.74	3,450.76	2,375.54

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	9,782.01	9,504.78	10,005.19	9,791.82	9,962.12
Total Non Current Assets	13,325.37	12,658.22	12,390.29	11,942.38	11,956.38
Total Current Assets	19,392.45	16,805.06	14,710.83	13,209.51	11,706.18
TOTAL ASSETS	32,717.82	29,463.28	27,101.12	25,151.89	23,662.56
Total Shareholder's Fund	26,706.43	23,407.78	20,841.69	18,326.53	15,763

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	4,133.91	3,237.65	3,325.90	3,755.20	3,068.45
Net Cash used in Investing Activities	-2,982.47	-2,376.14	-1,858.43	-2,374.39	114.39
Net Cash used in Financing Activities	-1,200.43	-958.29	-1,599.79	-1,239.51	-2,948.82

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	17,645	14,802.13	16,047.52	11,532.99	13,552
Total Expenses	12,698.03	11,610.63	12,243.14	8,748.99	10,587.69
Profit Before Tax	4,946.97	3,005.60	3,804.38	2,784	2,964.31
Profit After Tax	3,714.19	2,144.06	2,882.58	2,044.65	2,318.17
Operating Profit after Depreciation	4,967.22	3,213.77	3,831.31	2,829.07	3,000.36

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	3,692.51	3,810	3,927.99	4,022.73	4,088.54
Total Non Current Assets	16,195.39	14,225.34	14,114.01	12,771.56	11,378.60
Total Current Assets	14,857.84	13,371.13	11,335.04	10,192.18	9,027.06
TOTAL ASSETS	31,053.23	27,596.47	25,449.05	22,963.74	20,405.66
Total Shareholder's Fund	27,973.92	24,638.09	22,513.55	19,927.56	17,402.96

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	3,726.77	3,035.05	2,773.43	3,460.31	2,018.14
Net Cash used in Investing Activities	-2,882.90	-2,758.09	-2,464.14	-3,361.33	-1,127.18
Net Cash used in Financing Activities	-708.83	-424.77	-426.72	-65.80	-693.89

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	7,051.02	6,693.94	6,163.24	6,603.81	6,678.15
Total Expenses	5,165.43	4,978.14	4,847.38	4,856.28	4,944.40
Profit Before Tax	1,789.06	1,611.36	1,259.26	1,473.81	1,594.23
Profit After Tax	1,306.02	1,176.29	934.40	1,068.51	1,155.82
Operating Profit after Depreciation	2,076.20	1,875.99	1,565.19	1,932.16	1,910.07

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	4,775.03	4,501.05	4,036.66	4,381.33	4,234.44
Total Expenses	3,336.99	3,141.19	3,208.77	3,025.47	3,009.06
Profit Before Tax	1,578.47	1,430.45	1,280.61	1,477.14	1,358.20
Profit After Tax	1,178.16	1,055.94	1,038.40	1,114.14	1,029.69
Operating Profit after Depreciation	1,727.18	1,573.38	1,422.87	1,621.22	1,544.62

Cipla Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 1,413.73

S2 1,399.47

S3 1,373.93

Pivot 1,439.27

R1 1,453.53

R2 1,479.07

R3 1,493.33

Moving Average

20 SMA 1,481.79

50 SMA 1,486.59

100 SMA 1,544.53

200 SMA 1,514.66

Cipla Ltd Corporate Actions

Dividend

Bonus

Splits

Rights

AGM

EGM

Cipla Ltd

₹13/Share

Announcement Date 02 Aug 2024

Record Date 02 Aug 2024

Div Yield 650%

AGM Date: 26 Aug 2022

This is further to our letter dated 10th May, 2022, wherein it was informed that the Board of Directors of the Company have inter-alia recommended final dividend of Rs. 5/- per equity share (face value Rs. 2 /- per equity share) for FY 2021-22, subject to the approval of the shareholders at the ensuing 86th Annual General Meeting to be held on 26th August, 2022. Pursuant to Regulation 42 of SEBI LODR Regulations, the Company has fixed the ''Record Date'' for determining the member eligible for payment of final dividend. Notice of the 86th Annual General Meeting along with copy of Integrated Annual Report for FY 2021-22 (As Per BSE Announcement Dated on 02.08.2022) We hereby notify that the 86th Annual General Meeting (AGM) of the Company was held on Friday, 26th August 2022 at 3.00 pm through video conferencing / other audio-visual means (OAVM). Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 we are enclosing the following: 1. Speech by Dr Y K Hamied - Chairman 2. Presentation by Mr Umang Vohra - Managing Director and Global Chief Executive Officer 3. Proceedings of the AGM. Kindly take the above on record. (As Per BSE Announcement Dated on 26.08.2022) Cipla Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. (As Per BSE Announcement Dated on 30/08/2022) Please find enclosed the transcript of the 86th Annual General Meeting of the Company held on 26th August, 2022 through video conferencing / other audio-visual means. This transcript will also be uploaded on the Company's website at www.cipla.com This is for your information and records. (As per BSE Announcement Dated on 7/9/2022)

AGM Date: 10 Aug 2023

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed newspaper advertisement published in Business Standard and Sakal on 11th July 2023. Notice of the 87th Annual General Meeting along with a copy of the Integrated Annual Report for FY 2022-23. (As Per BSE Announcement dated on 18.07.2023) Pursuant to provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith: 1. Speech by Dr Y K Hamied- Chairman 2. Presentation by Mr Umang Vohra - MD & GCEO 3. Proceedings of the AGM Kindly take the above on record. Please find the attached voting result and scrutiniser report for the AGM held on today i.e. 10th August, 2023. (As per BSE Announcement Dated on 10/08/2023) Please find enclosed the transcript of the 87th Annual General Meeting of the Company held on Thursday, 10th August, 2023 through video conferencing / other audio-visual means. (As per BSE Announcement Dated on 24/08/2023)

AGM Date: 20 Aug 2024

Outcome of board meeting held on 10th May 2024 Please find enclosed Newspaper advertisement titled ' Notice of 88th AGM to be held through Video Conference / Other Audio-Visual Means, Record date and Final Dividend published in the Business Standard and Sakal on 18th July 2024. (As Per BSE Announcement dated on 18.07.2024) Notice of the 88th Annual General Meeting along with a copy of the Integrated Annual Report for FY 2023-24 (As Per BSE Announcement Dated on: 26/07/2024) Proceedings of the 88th Annual General Meeting. (As Per BSE Announcement Dated on: 20/08/2024) Please find enclosed the transcript of the 88th Annual General Meeting of the Company held on Tuesday, 20th August, 2024 through video conferencing/ other audio-visual means. (As Per BSE Announcement Dated on 30.08.2024)

Cipla Ltd Peer Comparison

Company	Price	Market Cap (in ₹ Cr)
Cipla Ltd	₹1,427.30	₹1,15,270.75
Sun Pharmaceuticals Industries Ltd	₹1,761.80	₹4,22,714.84
Divis Laboratories Ltd	₹5,818.40	₹1,54,460.24
Dr Reddys Laboratories Ltd	₹1,288.45	₹1,07,511.36
Torrent Pharmaceuticals Ltd	₹3,157.60	₹1,06,862.73
Mankind Pharma Ltd	₹2,563.35	₹1,05,755.34

Cipla Ltd News

Cipla's Goa-based facility gets one form 483 observation from US FDA

Cipla said that the United States Food and Drugs Administration (US FDA) has issued one observation in Form 483 to the manufacturing facility of its wholly-owned subsidiary Medispray Laboratories.

21 Jan 2025, 04:42 pm

Stock Alert: Cipla, Dixon Technologies, Tata Technologies, L&T Finance

21 Jan 2025, 08:35 am

Volumes spurt at Cipla Ltd counter

Cipla Ltd registered volume of 7.51 lakh shares by 10:46 IST on BSE, a 19.14 fold spurt over two-week average daily volume of 39249 shares

10 Jan 2025, 11:00 am

Cipla to table results

On 28 January 2025

07 Jan 2025, 10:09 am

Cipla Ltd soars 1.12%, gains for fifth straight session

Cipla Ltd is quoting at Rs 1546.2, up 1.12% on the day as on 12:44 IST on the NSE. The stock is up 20.65% in last one year as compared to a 9.67% jump in NIFTY and a 35.62% jump in the Nifty Pharma.

01 Jan 2025, 01:00 pm

Cipla Ltd Stock Analysis

Annual revenue for Cipla Ltd increased by 19.21% to ₹17,645 crore in FY 2024 from ₹14,802.13 crore in FY 2023.
Annual Net Profit for Cipla Ltd increased by 73.23% to ₹3,714.19 crore in FY 2024 from ₹2,144.06 crore in FY 2023.
Promoter Shareholding in Cipla Ltd decreased by 5.58% in the most recent quarter, from 30.86% in September 2024 to 29.13% in December 2024.
Cipla Ltd delivered a 1-year return of 1.35% compared to the Nifty 50, which provided a return of 8.41% as of the last trading session.
Cipla Ltd share price moved up by 0.38% from its previous close of INR ₹1,428. The latest Cipla Ltd share price is INR ₹1,433.40.
Cipla Ltd share price today has been at a low of 1,420.20 and a high of 1,440.85. Over the past 52 weeks, the Cipla Ltd share price has seen a low of 1,312 and a high of 1,702.05.

About Cipla Ltd

Cipla Ltd is an Indian multinational pharmaceutical company. It focuses on developing medications to treat diseases and various other medical conditions. The company operates in the pharmaceutical sector, providing a wide range of drugs, vaccines, and diagnostics. They even make contact lenses, animal health products, dietary supplements, and protein supplements.

Founded in 1935 by Khwaja Abdul Hamied as the Chemical, Industrial & Pharmaceutical Laboratories. The company’s headquarters are located in Mumbai, Maharashtra, India. The promoters of Cipla include the Hamied family, with Yusuf Hamied serving as the Chairperson and Umang Vohra as the CEO.

Cipla’s main products include medications for diseases, HIV/AIDS, oncology, and other therapeutic areas. The company is known for its innovation in developing affordable medications. For instance, they make antiretroviral drugs during the AIDS epidemic to make them more accessible.
Even though Cipla is a significant player in the pharmaceutical industry. It is not the largest in terms of market share or market capitalization in India. However, it is the third-largest drug producer in India.

The promoter shareholding in Cipla is a crucial aspect of its corporate structure. The Hamied family holds a substantial stake in the company. Here is a list of their top promoters -

Y K Hamied
M K Hamied
Umang Vohra
Samina Hamied
S Radhakrishnan

The registered office of Cipla is located at Cipla House, Peninsula Business Park, in Mumbai, Maharashtra, India. The company’s registrars and transfer agents are KFin Technologies Private Limited. They are situated in Selenium Tower B, Plot No. 31-32, Gachibowli in Hyderabad.

Cipla’s management team is led by Chairperson Yusuf Hamied and CEO Umang Vohra. They have been instrumental in steering the company towards growth and innovation. The company’s commitment to providing affordable healthcare solutions has made it a trusted name in the industry.

Vision and Mission

Cipla Ltd is a leading pharmaceutical company. Hence, it has a clear and compelling vision and mission that guide its operations and strategic decisions. These statements reflect the company’s commitment to better healthcare and making a positive impact on society.

Cipla’s vision is to be a leading global pharmaceutical company through its innovation and technology. They aim to provide high-quality, affordable healthcare solutions. The company aims to address the needs of patients around the world. In addition, to developing and delivering a wide range of pharmaceutical products. They envision a world where everyone can get essential medications, regardless of their situation. This vision drives the company’s efforts to expand its global footprint and enhance its product portfolio.

The vision statement emphasizes Cipla’s dedication to innovation. The company invests heavily in research and development to create better medications. It invests heavily towards cutting-edge technology and scientific advancements. They strive to stay at the forefront of the pharmaceutical industry. This focus on innovation ensures that the company can give effective treatments for various ailments.

Cipla’s mission is to provide access to high-quality and affordable medicines. This is to ensure that no patient is denied treatment due to financial constraints. The company’s mission statement underscores its commitment to social responsibility. Along with the role it can play in improving public health.

Cipla aims to make a difference in the lives of patients by offering a diverse range of pharmaceutical products. Their objective is to make medicines that meet the highest standards of quality and efficacy.
One of the key aspects of Cipla’s mission is its focus on affordability. The company is known for its efforts to make essential medications accessible to people in developing countries. Cipla’s pioneering work in producing affordable drugs for HIV/AIDS patients is a testament to its mission-driven approach. Moreover, by reducing the cost of life-saving medications, Cipla has played a major role in combating global health crises.

Cipla’s vision and mission are also closely aligned with its commitment to sustainability. The company recognizes the importance of environmental stewardship. Hence, it strives to minimize its ecological footprint. Cipla implements sustainable practices across its operations, from manufacturing to distribution.
This includes reducing waste, conserving energy, and promoting the use of renewable resources. Plus, by adding sustainability into its business model, it aims to create a healthier planet for future generations.

At the heart of Cipla’s vision and mission is a patient-centric approach. The company prioritizes the needs and well-being of patients in all its endeavors. Cipla engages with healthcare professionals and patients to understand their needs and challenges. This approach enables the company to develop solutions that tackle certain medical conditions.

Cipla’s patient-centric philosophy extends beyond the development of medications. The company also focuses on raising awareness about various health issues. It even provides education and support to patients and caregivers.They also empower patients with knowledge and resources that enable better care. This is how Cipla aims to enhance the overall healthcare experience and improve health outcomes.

Cipla’s vision and mission reflect its unwavering commitment to improving global healthcare. The company’s focus on affordability and patient-centricity drives its efforts to make a meaningful impact on society. With these core values, Cipla continues its legacy of excellence and compassion in the industry.